Geneva, Switzerland, May 26, 2021.


Abologix has been named one of the winners of the Venture Kick stage III start up competition.


“We are extremely happy to have been selected by Venture Kick to receive a CHF 150,000 CHF convertible loan. The funds will be used to advance the development of our asset and for advanced commercial and business development efforts. We are also very thankful to Venture Kick for their coaching and help in building our business case and for all the invaluable assistance received at the two Kickers Camps that we attended”.

said Dr. Ignacio Faus, co-founder and Chairman of the Board of Abologix.



Venture_Kick_Press_Release_Abologix
.pdf
Download PDF • 180KB


Geneva, Switzerland, November 1, 2020.


Abologix has been named one of the winners of the Venture Kick stage II start up competition.


“We are very happy to have passed this important milestone in the Venture Kick competition process. The 40.000 CHF to be received by Venture Kick will allow us to accelerate the company´s business development efforts”.

said Ignacio Faus, co-founder and Chairman of the Board of Abologix.

Geneva, Switzerland, Juy 24, 2020.


Abologix has been granted a 2 year Innosuisse Innovation project in collaboration with the University Hospital of Geneva (HUG). The HUG will be the research partner and Abologix the implementation partner.The collaboration plans to study the mechanism of action involved in arresting tumour growth through the selective blocking of Junction Adhesion Molecule JAM-C by monoclonal antibodies supplied by Abologix. These studies will lead to a deeper understanding of the molecular mechanisms of JAM-C blockage to inhibit growth and metastasis of certain lymphomas.